Drug prices & Part D
Medicare Part D Has No Announced Successor for GLP-1 Coverage Once the Bridge Program Closes at End of 2027
CMS paused the BALANCE Model for Medicare drug plans indefinitely in April 2026 after insurers did not sign up in sufficient numbers, leaving the 50-dollar-copay bridge as the only Part D GLP-1 pathway, now extended through December 2027.
By the Goodsurance editorial teamJuly 18, 2026
When CMS launched the Medicare GLP-1 Bridge on July 1, 2026, the program was designed as a six-month transition to a permanent model called BALANCE. In April 2026, CMS announced it was delaying the BALANCE Model for Medicare Part D indefinitely after plan sponsors representing less than the required 80 percent of Part D enrollment applied to participate. Insurers cited uncertainty about Part D market conditions and insufficient time to build actuarial models around GLP-1 utilization.
To preserve access, CMS extended the bridge from six months to 18 months, running through December 31, 2027. Under the bridge, eligible Part D enrollees with obesity or overweight and at least one related condition, such as high blood pressure or Type 2 diabetes, can access qualifying GLP-1 medications for a flat copay, provided they meet clinical criteria and are not already using a GLP-1 for a separately covered indication.
Medicare's GLP-1 bridge runs through 2027. There is no announced successor plan for what happens next in Medicare drug coverage.
CMS has not announced a replacement model for Medicare Part D after December 2027. The Medicaid component of BALANCE is moving forward separately: state Medicaid agencies could apply to join through July 31, 2026, and eligible Medicaid enrollees in participating states gain access as early as May 2026.
Medicare Rights Center has noted the uncertainty this creates for beneficiaries who start GLP-1 therapy under the bridge and may face a coverage gap after 2027 if no follow-on model is announced. CMS has said it will use data gathered during the bridge to inform future Part D planning.
In plain words
Medicare started covering GLP-1 weight-loss drugs for qualifying members on July 1, 2026. People pay a flat copay. This access runs through December 2027. A bigger permanent program was supposed to take over, but not enough insurance companies signed up, so it was put on hold with no date set. Right now there is no plan for what happens after the bridge ends in late 2027. A related program for Medicaid, the low-income health program, is still going forward in some states.
Understand the basics first
Source: CMS Innovation Center
Read at the source →